The FAME family of studies collectively add to the growing body of evidence demonstrating improved outcomes and cost-savings with the St. Jude Medical PressureWire. Further, there are currently more than 1,200 published articles with clinical evidence supporting St. Jude Medical’s FFR and OCT technologies.About Novation Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 100,000 members and affiliates of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 800 suppliers. Members of VHA, UHC, Children’s Hospital Association and Provista used Novation contracts to purchase approximately $49 billion in 2013. Novation has earned the coveted Ethics Inside Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance. Novation was also named on Ethisphere's World's Most Ethical Companies list, and is the only company in the health care industry to earn both distinctions for three consecutive years. To learn more about Novation, please follow @NovationNews. About St. Jude Medical St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com or follow us on Twitter @SJM_Media. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, was recognized by Novation as the 2013 Innovative Technology Supplier of the Year. Novation members selected the St Jude Medical ILUMIEN™ PCI Optimization System based on their experience using the technology to deliver improved patient outcomes. Novation works with its more than 100,000 members and affiliates to identify innovative technology that improves patient care or reduces the risk of harm to patients or providers, while simultaneously raising the standard of patient care and safety. “Novation’s goals of improving patient outcomes through innovative technology align with our mission at St. Jude Medical to create cost-effective medical technologies that save and improve lives,” said Joel D. Becker, president of the St. Jude Medical Americas Division. “We are pleased that Novation has recognized the many patient and economic benefits of our ILUMIEN System, and look forward to continuing our partnership with Novation as we pursue new treatments, efficiencies and ideas that improve the lives of people affected by expensive epidemic diseases.” The first-of-its-kind ILUMIEN System offers physicians advanced physiological and anatomical insight to improve the diagnosis and treatment of coronary artery disease. It helps physicians better understand which arteries should be treated and how best to treat them. The ILUMIEN System integrates both Fractional Flow Reserve (FFR) technology to measure blood flow blockage inside the coronary arteries and intravascular Optical Coherence Tomography (OCT) imaging technology to help physicians to visualize the area they are treating. Combined, the two technologies assist physicians in identifying culprit lesions responsible for a patient’s ischemia and provide physicians with precise measurements of lesion dimensions and vessel size and structure. St. Jude Medical recently launched the next generation ILUMIEN System, the ILUMIEN™ OPTIS™, which includes several first of its kind enhancements, including automated measurements and stent planning software tools. The OCT imaging technology now provides a real-time, three dimensional (3-D) reconstruction of the patient’s vessel, making it easier for physicians to visualize the area they are treating.